InSysBio to release CYTOCON DB Open version

NEWS
Press-Release
November 12, 2020

November 12, 2020

CYTOCON DB Open is designed for free public use

[Moscow – 12.11.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, has extended the variety of options to experience its CYTOCON DB with a new way. In general, the database allows to investigate the concentration of multiple species measured in different tissues of patients. Now InSysBio presents its public version entitled “CYTOCON DB Open”.

Previously there existed the demo version of CYTOCON Database or the commercial version accessible via purchasing the license. The new access mode to use or to get acquainted with CYTOCON DB is free. Actually, CYTOCON DB Open has the same functionality as CYTOCON DB. However, CYTOCON DB is updated on the monthly basis (approximately 1500 cell/molecule concentrations per month) while CYTOCON DB Open will be updated once per year. It concerns both content and functionality.

The development of the full version CYTOCON DB web application was launched about a year and a half ago. Now it embraces an impressive scope of data and features implemented (152 disease types, 75 tissues/physiological fluids, 353 molecules, 113 cell types and states, 14528 values of cytokine/cell concentrations; data extracted from 543 papers/other public source). The most meaningful sections comprise quantitative characteristics of patients, illnesses, and species concentrations. In fact, these species embrace the cells and cytokines concentrations observed in healthy people and patients who undergo treatment and those who don’t.

In should be outlined that CYTOCON DB Open, a version of the database designed for public use, is reduced in comparison with CYTOCON DB. Nevertheless, it has the same functionality and user-friendly interface that makes it simple to experience the usage of CYTOCON DB Open. Ekaterina Mogilevskaya, Head of Cytocon DB team, describes the most efficient way to apply the new version of the database, “Firstly, select necessary species, tissue types, diseases in Query section. You can choose cell markers and disease attributes. Than obtain your search results as a Table or Graph result. You can also export your selection results in csv format. Compare concentrations of cells/molecules recalculated into unified units from different sources. Or compare results for species of healthy controls and patients with different diseases”.

To access CYTOCON DB Open or to learn its content, please visit cytocon-open.insysbio.com.

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

June 2020
MoTuWeThFrSaSu
1
2
1. 02 Jun 2020 13:24 InSysBio to announce the launch of QSP model of COVID-19 The new open source project to be developed and updated Online InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
3
4
5
1. 05 Jun 2020 15:04 InSysBio to present IRT Navigator 3 InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.
6
7
8
1. 08 Jun 2020 15:30 InSysBio to perform the first step in development of COVID-19 QSP model InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
9
10
11
12
1. 12 Jun 2020 16:45 InSysBio to release the new version of Cytocon DB 1.1.6.4 We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.
13
14
15
16
17
1. 17 Jun 2020 15:48 InSysBio to welcome its new team member Dr. Neil Benson InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development (Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.
18
19
20
21
22
1. 22 Jun 2020 17:04 InSysBio team posters to be presented at AACR Virtual Annual Meeting II AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website
23
24
25
26
27
28
29
30
1. 30 Jun 2020 15:45 InSysBio to present COVID-19 QSP model further development InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
     
Upcoming Events
Tags
Latest News
10.09
InSysBio team to publish the new article in PSPJournal
04.09
InSysBio to launch Immune Response Template version 3.6.3 for QSP modeling
22.02
14th InSysBio’s Annual Internal Scientific Meeting
24.01
InSysBio to present the new Plugin for Sublime Text and Heta compiler Online
07.12
InSysBio to release public beta of fIVE Calculator